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Introduction
Depression is one of the most important public
health problems in the industrialised world, and is
associated with a substantial economic burden on
society. In the USA, Greenberg et al. (1) found a
total cost of 83.1 billion USD for the year 2000,
whereof 31% direct medical costs, 7% suicide-related
mortality costs and 62% costs for lost productivity at
work. The overall prevalence was estimated at 18.1
million cases, and the treated prevalence was esti-
mated at 7.9 million patients, for the year 2000.
There is a growing awareness of the need for a
long-term perspective in the treatment of affective
disorders (2–6). In many patients depression may
develop into a recurrent disease, and the risk of
recurrences seems to increase with the number of
previous episodes of depression (7). It is therefore an
important treatment goal to prevent recurrences.
Full remission means improvement to the degree
that the patient is asymptomatic, i.e. has no more
than minimal symptoms. In this context it is fruitful
to make a distinction between relapse and recurrence
(8). A relapse occurs if the depressive symptoms
return relatively quickly after an initial remission
from a depressive episode. If the patient has stayed
in full remission for a period long enough to qualify
as recovery, and depressive symptoms then come
back, it is a recurrence. Accordingly, treatment can
be divided into three stages: acute treatment phase,
continuation therapy to prevent relapse and mainte-
nance therapy to prevent recurrence (9).
A key question is for how long the patient should
remain on maintenance treatment after achieving
remission from an acute episode of depression. It is
often recommended that patients should be treated
for 4–6 months after going into remission (4,9), but
there is no wealth of studies with such a long or
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SUMMARY
Aims: The Prevention of Recurrent Episodes of Depression with venlafaxine XR for
Two Years trial has reported advantages with maintenance treatment for patients
with recurrent depressive disorder. The aim of this study was to assess the cost-
utility of maintenance treatment with venlafaxine in patients with recurrent major
depressive disorder, based on a recent clinical trial. Methods: A Markov simula-
tion model was constructed to assess the cost-utility of maintenance treatment for
2 years in recurrently depressed patients in Sweden. Risk of relapse and recurrence
was based on a recent randomised clinical trial assessing the efﬁcacy and tolerabil-
ity of maintenance treatment with venlafaxine over 2 years. Costs and quality of
life estimations were retrieved from a naturalistic longitudinal observational study
conducted in Sweden. Health effects were quantiﬁed as quality-adjusted life-years
(QALYs). Sensitivity analyses were conducted on key parameters employed in the
model. Results: In the base-case analysis, the cost per QALY gained of venlafax-
ine compared with no treatment was estimated at $18,500 over 2 years. In a
probabilistic sensitivity analysis, we found that maintenance treatment with venla-
faxine is cost-effective with 90% probability at a willingness to pay per QALY of
$67,000 or less. Our long-term analyses also indicate that even under conservative
assumptions about future risks of recurrences, maintenance treatment is cost-effec-
tive. Conclusion: The present study indicates that maintenance treatment for
2 years with venlafaxine is cost-effective in patients with recurrent major depres-
sive disorder.
What’s known
• Depression may develop into a recurrent disease,
and the risk of recurrences seems to increase
with the number of previous episodes of
depression.
• Full remission from depression is associated with
signiﬁcantly lower costs and higher quality of life
than no or only partial response.
• Hence, an important treatment goal is to achieve
remission and prevent recurrences.
What’s new
• This is the ﬁrst cost-utility study of long-term
maintenance treatment with venlafaxine in
patients with recurrent unipolar major depression.
• The results indicate that maintenance treatment
for 2 years in recurrent depression is cost-
effective.
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extensive meta-analysis has been published which
establishes the beneﬁts of antidepressant drug treat-
ment on the relapse risk (9). Most of the individual
studies used as a basis for the analysis are too short
for covering also the long-term recurrence risk, but
the results of the meta-analysis indicate that there is
no clear distinction between the continuation and
maintenance treatment effects.
Also from a health economic viewpoint it is
important to take full remission and the risk of
recurrence into account. Not surprisingly, full remis-
sion is associated with signiﬁcantly lower costs and
higher quality of life than no or only partial response
(10). The highest costs are for sickness absence
(about two-thirds), while the costs for antidepressant
treatments are only 6–8% of the total costs (11).
The purpose of the present study was to investi-
gate the cost-utility of 2-year maintenance treatment
with venlafaxine in patients with recurrent unipolar
major depression in the Swedish healthcare setting.
The analysis was based on a clinical trial comparing
venlafaxine to placebo (12).
Methods and materials
Cost-effectiveness analysis
The incremental cost-effectiveness ratio (ICER) is
deﬁned as:
ICER ¼
DC
DE
¼
C1   C0
E1   E0
ð1Þ
where DC is the difference in total cost between
intervention and no intervention, and DE is the dif-
ference in effectiveness between intervention and no
intervention.
Costs can be divided into two different categories:
direct and indirect costs. Direct costs included in the
present study include costs because of hospitalisa-
tions, outpatient visits and drugs. Indirect costs are
costs related to lost productivity because of the
illness. In this study, quality-adjusted life-years
(QALYs) will be used as an outcome measure, as it
is the most relevant measure of effectiveness from a
health-policy perspective.
The model
Cost-effectiveness analysis in depression generally
requires modelling, as all the required data are sel-
dom available from a single dataset over the relevant
timeframe. For the present analysis, a Markov model
was developed in line with the design of the Preven-
tion of Recurrent Episodes of Depression with VEN-
lafaxine XR for Two Years study (4), and is a
modiﬁed version of a previously published model
(13). The structure of the model is shown in the
state transition diagram in Figure 1. In a Markov
model, the patients are classiﬁed into a number of
different health states, each associated with a certain
cost and utility. As time progresses in the model, the
patients can move between different states (depres-
sive episode, remission, well and dead) according to
a set of transition probabilities. Patients may move
from one health state to another during a deﬁned
interval of time called a cycle.
The cycle length was set to 1 month and all
patients are followed through the model for 2 years
(equal to the length of the clinical trial). Given the
disease characteristics and the 2-year follow-up time,
monthly intervals were appropriate for the cycle
length in the Markov model, because this is a clini-
cally meaningful cycle length and gives good preci-
sion in the model. There is always a probability to
remain in the same state or to die. All the patients
begin in the remission health state, because that is
the starting point of the maintenance treatment
phase. Each month a patient has a probability of
relapsing or to die. If a patient dies, he will move to
the dead health state and remain there for the rest of
the simulation (arrows to the dead health state were
excluded to simplify the ﬁgure). If the patient
relapses he will move to the relapse state. In the base
case, patients were not allowed to remit from a
relapse during the maintenance treatment phase, to
model the cost-effectiveness of venlafaxine as close to
the clinical trial design as possible. However, in sen-
sitivity analysis patients were allowed to remit from a
relapse, turn well after 6 months of being in the state
remission, and recur to a depressive episode after
having recovered, i.e. from being in state well (see
dotted arrows in Figure 1).
Clinical trial data
The present analysis was based on a recent clinical
trial (12). The trial aimed at assessing the efﬁcacy
and tolerability of venlafaxine as maintenance
treatment in recurrent depressive patients. The dou-
ble-blind randomised multicentre trial started with a
10-week treatment period during the acute phase of
Episode
Dead
Remission
Episode
Dead
Well
Figure 1 Structure of the Markov cohort simulation model
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phase for patients who responded to treatment [17-
item Hamilton Rating Scale for Depression (HAM-
D17) total score £ 12 or 50% decline from baseline]
and remitters (HAM-D17 £ 7). Patients treated with
venlafaxine, and who had satisfactory response or
remission also after the continuation phase, were
randomised 1 : 1 between venlafaxine and placebo in
a maintenance phase. The maintenance phase was in
turn divided into two consecutive 12-month periods,
A and B. At the end of maintenance period A,
patients who continued to respond to venlafaxine
were once again randomised 1 : 1 between venlafax-
ine and placebo in maintenance period B. The results
from the trial were based on intention to treat.
The purpose of the maintenance phase was to
investigate the effect of maintenance treatment with
venlafaxine on the recurrence rate compared with
placebo. Placebo is a relevant comparator in this
phase, as the optimal duration of maintenance treat-
ment is still an issue for debate.
The inclusion criteria in the study were age
‡ 18 years, fulﬁlling the Diagnostic and Statistical
Manual of Mental Disorders criteria for major
depressive disorder with at least two episodes of
major depression, excluding the current one, in the
past 5 years and with at least 3 months between the
end of the previous episode and the beginning of the
present one. The patients should also have had
depressive symptoms for at least a month prior to
randomisation, with a HAM-D17 score ‡ 20 at
screening, and a HAM-D17 score larger than 18 at
randomisation.
Patients who failed to respond to venlafaxine dur-
ing the acute (and later phases) discontinued the
study. Patients with a history of treatment resistance
or psychiatric comorbidities such as bipolar disorder
and eating disorder were excluded, as were patients
with a primary diagnosis of panic disorder, obsessive
compulsive disorder, generalised anxiety disorder,
social phobia or posttraumatic stress disorder within
6 months prior to screening.
The primary efﬁcacy measure was the HAM-D17
scale, which was administered at each monthly visit.
The primary endpoint of the study was time to
recurrence of depression, with recurrence deﬁned as
a HAM-D17 score > 12 and a HAM-D17 score reduc-
tion of at most 50% compared to acute-phase base-
line at two consecutive visits.
Secondary efﬁcacy measures included rate of
response (HAM-D17 total score £ 12 or 50% decline
from baseline), remission (HAM-D17 £ 7), Clinical
Global Impression – Severity scale (CGI-S), Medical
Outcome Short Form (36) Health Survey, and some
other standard scales.
Target patient group
The target patient group included in the model was
based on the study population included in the clini-
cal trial (12). These patients were high-risk patients
with recurrent depressive episodes. Patients included
in the analysis had been successfully treated with
antidepressant therapy for a depressive episode, and
had remitted from the episode with a HAM-D17
score of £ 7, which is a generally accepted level of
clinical remission in depression (14). The mean age
of the study sample was 42 and 67% of the sample
were women. On average, the patients were moder-
ately depressed at inclusion to the clinical trial (CGI-
S mean score of 4.3 or HAM-D17 score of 22).
Health economic data
Cost data for the ‘episode’ and ‘remission’ health
states in the model were retrieved from the naturalis-
tic observational study ‘Health Economic Aspects of
Depression In Sweden’ (HEADIS) conducted in
Swedish primary care (11). The patient characteris-
tics of the HEADIS study corresponded well with the
study population of the clinical trial, with a mean
age of 47, 67% women, and a CGI-S mean score of
3.9 (11), which means that the costs from this study
should be representative also for patients with the
characteristics in the clinical trial. Cost data were
incorporated both from a healthcare payer and a
societal perspective. In the healthcare payer perspec-
tive, the costs correspond to the amount paid or
reimbursed within the healthcare system. The societal
cost includes the total expenditure because of the
disease, regardless of who covers the cost. This
includes costs both for health care and for sick leave
paid by employers and social insurance funds. Data
on resource use included primary care visits, hospital
visits and visits to other health professionals (e.g.
psychologists and counsellors). Productivity costs
included productivity lost because of absenteeism.
Data on quality of life for depressive episode and
remission, measured with the EuroQoL-5D health
status questionnaire, were retrieved from the HEA-
DIS study (15), and was used to estimate QALYs in
the model. The data from the HEADIS study showed
that remission was an important predictor of health-
related quality of life, whereas other demographic
and clinical variables were not statistically signiﬁcant
(10,15). The results from the HEADIS study are thus
applicable to use for the health states ‘Episode’ and
‘Remission’ in the Markov model (10). Adjustments
for multiple comparisons were not performed for the
parameter estimations, as point estimates were used
in the cost effectiveness model. In the sensitivity
analysis, the model was extended, which allowed for
patients ending up in the health state ‘Well’, and a
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health-related quality of life in the general popula-
tion conducted by Burstro ¨m et al. (16). The cost and
utility values applied in the model are summarised
in Table 1.
Cost of intervention
The cost of venlafaxine was based on mean dosages
given in the clinical trial and drug prices listed in the
National Pharmaceutical Drug Price list (http://
www.fass.se). Venlafaxine was administered at an
average dosage of 217 mg the ﬁrst year and 200 mg
the second year. A weighted daily drug cost was cal-
culated for both periods of the 2-year maintenance
treatment phase.
Cost of adverse effects
The clinical trial reported no signiﬁcant differences
in adverse effects between the treatment arms. How-
ever, costs because of the most common adverse
effects were included in the model in the sensitivity
analysis.
Transition probabilities
Risk of relapse
The relapse risk of a new episode during the
maintenance treatment period was based on the
combined follow-up data retrieved from the clinical
trial (12). Relapse was deﬁned as a HAM-D17 score
of ‡ 12. A Weibull regression model was estimated
on survival data from the clinical trial (Wyeth,
data-on-ﬁle) measuring time to relapse between the
two treatment arms (Table 2). The Weibull distri-
bution was chosen as it is suitable for modelling
data with hazard rates that increase or decrease
over time, and allows for the estimation of the
probability of an event in different time intervals
after the starting point. The monthly risk of relapse
was, thereafter, estimated and employed in the
Markov model.
Probability of remitting
In the base case it was not taken into account that
patients could remit from a relapse in the maintenance
treatment phase. As a sensitivity analysis, the model
was extended to allow for this, and monthly estimates
of probabilities of remitting were derived from the
naturalistic observational study HEADIS (10).
Mortality risk
Mortality rates were taken from the general popula-
tion in Sweden (17), and based on the literature it
was assumed that patients having a depressive epi-
sode had an increased relative risk of dying because
of suicide of 20.4 (18).
Table 1 Data included in the model
Parameter Data (95% CI) Source
Costs by states ($⁄month)
Well* 0
Episode
Direct healthcare costs 433 (382–518) (10)
Indirect costs 938 (774–1108) (10)
Remission
Direct healthcare costs 273 (157–341) (10)
Indirect costs 555 (437–681) (10)
Dead 0
Health utility weights
Well* 0.86 (SE 0.009) (16)
Episode 0.57 (0.52–0.61) (10)
Remission 0.81 (0.78–0.84) (10)
Dead 0
Transition probabilities
Risk of relapse Survival function (4)
Probability of remitting* Survival function (10)
Risk of re-relapsing* 0.15 (9)
Risk of recurrence (episodes⁄year)* 0.20 (19)
Increased risk of recurrence with previous episodes (hazard ratio) 1.15 (1.11–1.18) (20)
Increased risk of death with depressive episode (SMR) 20.4 (SE 1.1) (18)
*Included in the sensitivity analysis. CI, conﬁdence interval; SMR, standardised mortality ratio.
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In a sensitivity analysis it was also allowed for
re-relapses, recovery (health state well) and recur-
rence. Geddes et al. (9) have conducted a thorough
meta-analysis based on clinical trials, and estimated
the risk of relapse to be 0.15 during 6 months of
treatment with antidepressants. The risk of recur-
rence was set to 0.20 per year (19). However, the risk
was assumed to increase with the number of previ-
ous episodes (hazard ratio 1.15) (20).
Analysis
Base-case analysis
Costs were reported both from the societal perspec-
tive and from the healthcare perspective. The differ-
ence is that the former also includes productivity
losses because of absenteeism from work. All costs
were reported in year 2005 values and given in US
dollar currency ($1 = SEK7.5). As recommended by
most national pharmaceutical beneﬁts boards a
yearly discount rate of 3% was used for both costs
and effects (21). Effects were measured in terms of
QALYs. In the base case, the time frame of the analy-
sis was set equal to the maintenance treatment phase
of the clinical trial.
Stochastic analysis
To capture some of the uncertainty in the underlying
parameters a stochastic analysis was performed for
the base-case scenario. Parameters included in the
stochastic analysis are listed in Table 3. Where
patient-level data was available (costs, quality of life
and risk of relapse) the statistical bootstrapping
method was employed (1000 replications) using the
bias-corrected accelerated bootstrap method (22), as
suggested by previous researchers (23). The stochas-
tic analyses were based on Monte-Carlo simulations
with 10,000 replications.
Sensitivity analysis
The following key parameters were tested for in the
sensitivity analysis: the model time frame (varied
from 6 months to 4 years), discount rates (varied
from 0% to 10%), drug acquisition cost (varied by
±50%), cost of adverse effects, relapse risk (varied
±20%), and mortality risk (varied ±20%). Further-
more, the Markov model developed for the within-
Table 2 Weibull survival function on time to relapse comparing venlafaxine with placebo (months), no hazard
Coefﬁcient SE z P>z 95% CI
Venlafaxine* )0.546 0.281 )1.94 0.052 )1.097 0.004
Constant )2.561 0.263 )9.74 0 )3.076 )2.045
*A dichotomous variable was included: venlafaxine for 1 and placebo for 0. LR v1
2 = 3.84; p = 0.05. LR, likelihood ratio.
Table 3 Parameters given measures of uncertainty in the probabilistic analysis
Parameter Source Method
Costs by states
Episode
Direct healthcare costs (10) Bootstrapping mean estimate
Indirect costs (10) Bootstrapping mean estimate
Remission
Direct healthcare costs (10) Bootstrapping mean estimate
Indirect costs (10) Bootstrapping mean estimate
Quality of life
Episode (10) Bootstrapping mean estimate
Remission (10) Bootstrapping mean estimate
Transition probabilities
Risk of relapse (4) Bootstrapping Weibull regression
Mortality
Risk of death (SMR) (18), (17) Normal distribution
SMR, standardised mortality ratio.
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rences and recovery and to be able to project the
cost-effectiveness of maintenance treatment over
long term.
Results
Base case
In base case, maintenance treatment for 2 years with
venlafaxine was assessed compared with no treat-
ment. From the societal perspective treatment with
venlafaxine came at incremental cost of $1020 over
2 years, but generated a gain in QALYs of 0.055. This
resulted in an ICER of $18,500. The corresponding
results from the healthcare perspective were an incre-
mental cost of $2000 over 2 years, a gain in QALYs
of 0.055, and a cost-effectiveness ratio of $36,000 per
QALY gained (Table 4).
Stochastic analysis
In the probabilistic sensitivity analysis we assessed
the uncertainty around our base-case results. The
combined uncertainty in the analysis is reported as a
probabilistic cost-effectiveness acceptability curve
(Figure 2). At a willingness to pay for an additional
QALY of $40,000, venlafaxine is cost-effective in the
maintenance treatment for recurrent depression at a
probability of 80%, while at a willingness to pay for
an additional QALY of $67,000, it is cost-effective at
a probability of 90%.
Sensitivity analysis
In the sensitivity analysis, key parameters in the
model were varied, to capture the uncertainty in the
ICERs. All results from the sensitivity analysis are
summarised in Table 5. In the base case, we used the
data from the clinical trial for the estimation of risk
of relapse during the maintenance treatment phase.
Varying the relapse risk by ±20% resulted in a range
of $11,900–27,600 for the cost per QALY gained. In
the base case, we assumed an increased mortality rate
of 20 times that of the general population. By vary-
ing this assumption by ±20%, the ICER once again
ranged from $12,000 to $27,600.
In the base case, we employed the same time
frame for the analysis as the follow-up length chosen
in the clinical trial. By decreasing the treatment
length and time frame for the analysis, we obtained
an ICER ranging from $86,100 per QALY gained
when only treating for 6 months after remission to
$18,500 for 2 years (base case).
Costs and effects were discounted with an
annual 3% rate in the base case. Varying the dis-
count rates from 0% to 10%, resulted in an ICER
ranging from $17,600 to $19,200 per QALY gained.
When including costs associated with adverse
effects from treatment, the ICER improved to
$17,800 when compared with $18,500 per QALY
gained in the base case. In the base case, only pro-
ductivity costs because of sick leave were included
in the analysis. As a sensitivity analysis, we also
included productivity costs because of reduced
working capacity, based on results from an Ameri-
can study be Stewart et al. (24), which indicated
that 81% of the lost work productivity because of
depression are explained by reduced performance
while at work. Our results showed that venlafaxine
is cost-saving compared with no maintenance
treatment when reduced work performance is
included.
Long-term analysis based on extended model
In our base-case analysis, we aligned the design of
the model closely to that of the clinical trial. This
did, however, not allow for multiple recurrences and
recovery and thus an extended Markov model was
developed. The extended model resulted in ICERs
varying from $69,500 with a 6-month time frame to
Table 4 Base-case results
DCosts ($) DQALYs ICER
Venlafaxine vs. placebo
Healthcare perspective 1978 0.055 35,968
Societal perspective* 1020 0.055 18,548
*Societal perspective includes indirect costs for productivity los-
ses in addition to direct healthcare costs. ICER, incremental
cost-effectiveness ratio; QALY, quality-adjusted life-year.
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
1 
0 
10 000 
20 000 
30 000 
40 000 
50 000 
60 000 
70 000 
80 000 
Willingness to pay ($/QALY) 
P
r
o
p
o
r
t
i
o
n
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
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628 Cost-effectiveness of maintenance treatment in depression
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, April 2008, 62, 4, 623–632$32,400 with a two-treatment period and time frame
for the analysis. Based on the extended model long-
term projections were conducted of the cost-effec-
tiveness of prophylactic treatment. Extending the
time frame of the analysis to 3 and 4 years, resulted
in further decrease of the ICER (Table 5). Longer-
time horizons of the analysis resulted in cost-
effectiveness ratios of around $17,600 (Figure 3).
Assuming that prophylactic treatment reduces the
long-term risk of recurrences improves the ICER
even further.
Discussion
Based on a clinical trial assessing the efﬁcacy of
maintenance treatment with venlafaxine in recurrent
depression internationally, we assessed the cost-effec-
tiveness of this intervention. Our results indicate
that, compared to not providing maintenance treat-
ment to this high-risk group of depressed patients,
venlafaxine is likely to be cost-effective within the
conventional margins of willingness to pay for addi-
tional health beneﬁts in Sweden. Our analysis indi-
cates that the length of maintenance treatment and
analysis perspective is of importance when assessing
the economic beneﬁts of maintenance treatment in
this patient group.
There is no deﬁnite threshold limit regarding the
highest acceptable cost per QALY gained (25). The
WHO argue for international values of three times
the gross domestic product per capita for developed
countries (26). In the USA, threshold values of
$50,000–100,000 per year of life gained have been
recommended in some studies (27,28). In a survey
among health economists about what threshold value
to use in a cost-effectiveness analysis, Newhouse (26)
reported a mean value of $60,000 per year of life
gained. In Sweden, values around $90,000
(SEK650,000) have been mentioned based on the
willingness to pay for saving lives on the Swedish
roads (29).
The current analysis of the cost-effectiveness of
maintenance treatment was based on patients having
reached clinical remission from an acute depressive
episode. It is widely recognised that full remission is
of high importance when treating an acute phase of
a depression, both from a clinical point of view (30),
as well as from an economical point of view
(10,13,31). However, there is a growing concern
regarding the need for preventive treatment in recur-
rent depressive patients. Most international treatment
guidelines for depression emphasise the importance
of prophylactic treatment of patients with recurrent
depression (32–35), suggesting that the treatment
period should be at least 1–2 years. In Sweden, there
Table 5 Sensitivity analysis
DCosts ($) DQALYs ICER
Relapse risk
+20% 1323 0.048 27,567
+10% 1167 0.052 22,446
Base case 1020 0.055 18,548
)10% 882 0.060 14,693
)20% 751 0.063 11,922
Mortality risk
+20% 1311 0.047 27,889
+10% 1160 0.051 22,753
Base case 1020 0.055 18,548
)10% 889 0.059 15,076
)20% 768 0.064 12,000
Simulation time frame
6 months 517 0.006 86,111
1 year 798 0.02 39,907
1.5 years 951 0.055 25,697
2 years* 1020 0.099 18,548
Discount rate (costs and effects)
0% 1059 0.060 17,644
3%* 1020 0.055 18,548
5% 1008 0.054 18,664
10% 978 0.051 19,179
Acquisition cost of venlafaxine
)50% )169 0.055 Dominance
)30% 545 0.055 9910
)10% 782 0.055 14,225
+10% 1258 0.055 22,873
+30% 1733 0.055 31,518
+50% 2209 0.055 40,165
Costs of adverse effects 972 0.055 17,680
Including productivity
costs at work
)4413 0.055 Dominance
Extended model§
6 months 486 0.007 69,467
1 year 732 0.020 36,607
2 years* 1524 0.047 32,428
3 years– 2032 0.069 29,445
4 years– 2850 0.091 31,314
*Base-case assumptions. Costs were estimated for the most
common adverse effects in the clinical trial, resulting in an
average increased cost of $48 for the placebo group compared
with patients treated with venlafaxine. Productivity cost
because of reduced working capacity estimated at $4200 per
month in 50% of patients in a depressive episode in the model
(24). §Based on an extended model allowing for re-relapse and
recovery and recurrence within the time frame studied. –Based
on maintenance treatment for 2 years and halved probability of
remission for placebo patients when compared with active
treatment. ICER, incremental cost-effectiveness ratio; QALY,
quality-adjusted life-year.
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depression, but the Swedish National Board of
Health and Welfare is currently developing such
guidelines. However, in a recently ﬁnalised review by
the Swedish Council on Technology Assessment in
Health Care, it is ﬁrmly concluded that maintenance
treatment is effective in recurrent depressive patients
(36). The present analysis justiﬁes not only that there
are clinical beneﬁts with maintenance treatment in
recurrent depression, but also that it is likely to be
cost-effective within the current levels of willingness
to pay for an additional QALYs (37).
The present analysis is to our knowledge the ﬁrst
economic evaluation assessing the cost-effectiveness
of maintenance treatment of recurrent depression in
Sweden. Moreover, only a few earlier studies of this
type have been conducted internationally, and no
study evaluating the maintenance treatment with
venlafaxine in recurrent unipolar depressive disorder.
Dardennes et al. (38) conducted a cost-utility analy-
sis of maintenance treatment in recurrent depression
in France from the perspective of the French sick-
ness fund, comparing milnacipran with no treatment
over a time period of 12 months. The authors pre-
sented a cost per QALY gained at FF 23,900–142,100
depending on the risk of hospitalisation in the
patient population studied. Another study in a
French setting found ﬂuvoxamine to be cost-effective
as maintenance treatment in recurrent depression
(39). Nuijten (40) assessed the cost-effectiveness of
implementing the Dutch clinical treatment guidelines
of continuation treatment in major depression, and
concluded that continuation treatment ought to be
extended to maintenance treatment to reach levels of
cost per QALY gained considered to be cost-effec-
tive. Kamlet et al. (8) came to the conclusion that
antidepressant maintenance therapy for 3 years is
cost-saving when compared with placebo or inter-
personal therapy alone in the area of Pittsburgh in
the USA. Despite a rather small number of previous
assessments of the cost-effectiveness of maintenance
treatment in recurrent depression internationally,
our study adds to a growing understanding that
maintenance treatment is not only effective in pre-
venting episodes in recurrent depressive disorder,
but also beneﬁcial from an economical point of
view.
Our sensitivity analysis shows that the most criti-
cal parameter for the ICER is the maintenance treat-
ment period. We reach an ICER above $80,000 with
a short prophylactic treatment period (6 months),
whereas it decreases with longer treatment period
and follow-up. In a sensitivity analysis, productivity
costs because of reduced performance while at work
were included based on American ﬁndings (24). This
analysis resulted in cost-savings in favour of prophy-
lactic treatment. The base-case analysis in the present
work, did not allow for repeated relapses⁄recurrences
within the time frame of the analysis. Allowing for
these consequences did, however, only increase the
ICER marginally. The probabilistic sensitivity analysis
performed showed that the cost-effectiveness results
for venlafaxine were stable for reasonable variations
in key parameters.
There are, however, a number of limitations with
the current analysis, which should be considered
when interpreting the results presented. First, the
current analysis is based on effect data from a multi-
centre clinical trial, and there are several concerns
when applying clinical effects of a treatment from
one setting to another. Second, the health economic
data employed in the current analysis was based on
an observational study carried out in Swedish pri-
mary care settings. Although the characteristics of
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the patients included in the Swedish observational
study, we might underestimate costs of hospitalisa-
tion, as relatively few patients were hospitalised in
that study. As a consequence of this underestimation,
our cost-effectiveness results are probably conserva-
tive. Third, the analysis of the cost-effectiveness was
based on a fairly short follow-up period, and more
longitudinal follow-up studies are needed to be able
to evaluate the cost-effectiveness of maintenance
treatment over a longer time period than 2 years.
Fourth, venlafaxine was evaluated compared with
placebo in this study, which was appropriate as the
optimal duration of maintenance treatment is still an
issue for debate. Whether venlafaxine would be cost-
effective compared also to other antidepressants in
the maintenance phase was beyond the scope of this
study, as it would require direct comparative data
during the maintenance phase, or at least long-term
data from a comprehensive meta-analysis. Investiga-
tion of this issue is left for further research.
Conclusions
A growing body of literature and international treat-
ment guidelines argue for preventive treatment in
recurrent depressed patients. Based on a recent
clinical trial, our results indicate that maintenance
treatment for 2 years in recurrent depression is cost-
effective in the Swedish treatment setting.
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